Methotrexate and rheumatoid arthritis associated interstitial lung disease

Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed. We aimed to evaluate the association of prior MTX use with development of RA-ILD.Through a case-control study design with discovery and international replication samples, we examined the association of MTX exposure...